Home Alzheimer’s Disease OmniSeq Employing RNA Sequencing Assay to Investigate Personalized Immunotherapy Combos

OmniSeq Employing RNA Sequencing Assay to Investigate Personalized Immunotherapy Combos

OmniSeq and the University of Pittsburgh Medical Center (UPMC) are partnering ahead of a phase 2 clinical trial (NCT04326257) examining patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), according to a press release.

OmniSeq will employ its RNA sequencing gene expression profile assay for the selection of immunotherapy combinations for patients with this disease type enrolled in the trial’s population.

By employing a more personalized approach for the selection of novel immunotherapeutic combinations moving forward, response rates should improve and better predictive biomarkers of efficacy should develop further.

“We are excited for this collaboration and to be able to offer the gene expression profile technology to [patients with recurrent/metastatic HNSCC] who have failed prior immunotherapy,” principal investigator and co-leader of the Head & Neck…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Recent Comments